T-DM1 with concurrent radiotherapy in HER2-positive breast cancer: preclinical evaluation and mechanisms, prediction, and exploration of adverse effects

T-DM1 with concurrent radiotherapy in HER2-positive breast cancer: preclinical evaluation and mechanisms, prediction, and exploration of adverse effects

Abstract Human epidermal growth factor receptor 2 (HER-2) serves as a pivotal target for breast cancer treatment and a vital prognostic marker. Anti-HER-2 therapies, which are integral to the management of HER-2-positive breast cancer, including monoclonal antibodies (e.g., trastuzumab and pertuzuma...

Full description

Saved in:
Bibliographic Details
Main Authors: Guangmin Wan, Lu Yang, Quan Wang, Gang Xu
Format: Article
Language:English
Published: Springer 2025-05-01
Series:Discover Oncology
Subjects:
T-DM1
Radiotherapy
HER-2
ADCs
Adverse effects
Online Access:https://doi.org/10.1007/s12672-025-02239-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s12672-025-02239-2

Similar Items